www射-国产免费一级-欧美福利-亚洲成人福利-成人一区在线观看-亚州成人

US EUROPE AFRICA ASIA 中文
Business / Companies

GSK puts China corruption case behind it, forms new business model

By Cecily Liu (chinadaily.com.cn) Updated: 2015-10-22 20:17

GSK puts China corruption case behind it, forms new business model

The logo of GlaxoSmithKline (GSK) is seen on its office building in Shanghai in this July 12, 2013 file photo.[Photo/Agencies]

GlaxoSmithKline emerged from its corruption scandal in China in 2013 to form a new business model in the country and is committed to further expansion there, chief executive officer Andrew Witty told China Daily in London on Wednesday in an exclusive interview.

"We think it's a very sad and disappointing experience, but we've reacted constructively and learnt many things. And now we understand China better, we have a new commercial model and incentive system, which is in step with the expectations of the Chinese government," Witty said.

In 2013, GSK was found by the Chinese authorities to be bribing doctors to prescribe its drugs to patients, and after a court trial the company was made to pay a $489 million fine in 2014.

Witty said that GSK has since developed a commercial model with improved technology and transparency.

The transparency of the model allows GSK to monitor its sales staff to make sure no bribe is paid to doctors, and the continuously improving technology allows doctors to obtain much more information about GSK drugs to aid their decision making process when prescribing medicine.

"We've made it clear to the doctors in China about our changes and have spent a great deal of time to explain to them the reasons for us making the changes. We have received a lot of understanding and appreciation from doctors about our approach," Witty said.

As well, GSK has invested in continuously improving technology to reduce the cost of the medicine, Witty said.

Speaking about China's healthcare market environment, Witty said that China is a country that it takes time to understand, just like any other country, and understanding China encompasses its economic policies, economic direction and regulation.

He said that "GSK is lucky to be a guest of China" and will fulfill its responsibility to deliver the medicine that are up to expectations.

GSK also announced on Wednesday that it will invest 2 million pounds in a 3 year partnership with the National Health and Family Planning Commission of China to train seven thousand Chinese doctors in the diagnosis and treatment of Hepatitis B.

Witty said that this investment reaffirms GSK's long term commitment to serving China and the healthcare needs of patients in the country.

Hepatitis B is a high priority in China, with about 20 million sufferers across the country remaining untreated.

"We think it is important that we're doing the training in partnership with the Chinese government, so that we can make sure what we have invested in will help to address issues that are of real importance to China," said Witty.

He said that the Hepatitis B investment is similar to GSK's investment into training Chinese doctors in the treatment of respiratory conditions and chronic obstructive pulmonary disease, announced last month, which are also healthcare priority areas identified by the government.

The Hepatitis B program, to be run over three years, and delivered by the Development Center for Medical Science and Technology, National Health and Family planning Commission of China, will help doctors understand how to diagnose, treat and provide ongoing management to patients with Hepatitis B.

Witty said that China will remain important to GSK over the long term, in particular because it has a large population, meaning that from a commercial perspective the sales potential is great, and from a research perspective it can provide a valuable environment to develop medicine that GSK can use globally.

GSK was ranked as the world's sixth-largest pharmaceutical company in 2014, with revenue of 23 billion pounds.

GSK has already committed 6 million pounds for public health initiatives in China over the next five years, with around 4 million being spent on independent GP training, the company said in a statement.

To contact the reporter: cecily.liu@mail.chinadailyuk.com

Hot Topics

Editor's Picks
...
主站蜘蛛池模板: 手机看a | 国产午夜精品久久久久九九 | 精品国语_高清国语自产 | 国产视频自拍一区 | 永久免费精品视频 | 在线观看成年视频 | 成人午夜视频一区二区国语 | 久久免费观看国产精品 | 亚洲天堂爱爱 | 一区二区三区四区免费视频 | 亚洲高清一区二区三区四区 | 国产亚洲精品激情一区二区三区 | 国产香蕉成人综合精品视频 | 亚州一区二区 | 国产欧美日韩综合精品一区二区三区 | 孕妇孕妇aaaaa级毛片视频 | 99久久精品免费精品国产 | 国产美女视频网站 | 中文字幕乱码系列免费 | 免费男女乱淫真视频播放 | 久久精品国产免费观看99 | 免费一级欧美大片视频在线 | 成人高清在线观看 | 男人的天堂免费视频 | 日韩欧美久久一区二区 | 麻豆一级片 | 精品女厕沟底拍撒尿 | 综合另类| 99免费在线视频 | 国产成年人在线观看 | 99久久精品免费看国产一区二区三区 | 国产午夜免费福利红片 | 国产中文99视频在线观看 | 久久亚洲精品永久网站 | 日韩精品小视频 | 91久久精品国产亚洲 | 午夜宅男宅女看在线观看 | 最新69成人精品毛片 | 国产一区二区三区美女在线观看 | 在线视频一区二区三区 | 国产自线一二三四2021 |